Testing Times
The Emergence of the Practolol Disaster and its Challenge to British Drug Regulation in the Modern Period
Bibliographic Data
| ID | 12208331 |
|---|---|
| Authors | John Abraham (0000-0003-3643-0128, University of Sussex, corresponding author), Julian Abraham (0000-0003-0643-0274), Courtney Davis (0000-0002-9425-9886) |
| Year | 2006 |
| Volume | 19 |
| Issue | 1 |
| Pages | 127-147 |
| Publication date | 2006-02-20 |
| Peer Reviewed | Yes |
| Open Access | No |
| Type | ARTICLE |
| Venue | Social History of Medicine (JOURNAL) |
| Journal identifiers | ISSN: 0951-631X • E-ISSN: 1477-4666 |
| Publisher | Oxford University Press (OUP) (PUBLISHER) |
| DOI | 10.1093/shm/hkj005 |
| PMID | 17153164 |
| OpenAlex | W2063777393 |
| Language | EN |
| Citations received | 13 |
| References cited | 15 |
This article analyses how practolol, the first British drug disaster of the modern, post-thalidomide regulatory period, related to the pharmaceutical industry, the medical profession and government regulation of patients' health. Drawing on comparison with the USA, it argues that, contrary to public expectation and perception, the aftermath of thalidomide did not give rise to strident British drug control, imposing the highest possible safety standards on the pharmaceutical industry. Rather, there existed a culture of reluctant regulation that was characterised by continued optimism about, and trust in the purported benefits of new drugs among manufacturers and regulators in the United Kingdom, together with commitment to the protection of the industry and its institutional support for the medical profession. In particular, British regulators were willing to allow new drugs on to the market, fully aware of uncertainty about their safety, but unwilling to be pro-active in issuing warning letters about risks and requiring 'certainty' before acting to withdraw a product. Even after the practolol disaster, the British system was unable to reform itself to construct more rigorous and pro-active monitoring of drug risks. This was because of conflicts with industry interests
Business · Drug · Generic drug · Government (linguistics · Pharmaceutical industry · Political science · Practolol · Scrutiny · Historical and Scientific Studies · Medical Malpractice and Liability Issues · Medicine · Pharmaceutical industry and healthcare · Law · Pharmacology
The Limits of Corporate Social Responsibility
From drug crises to regulatory change
A comparative analysis of risk management strategies in European Union and United States pharmaceutical regulation
Pharmaceutical innovation and its crisis
Drug Trials and Evidence Bases in International Regulatory Context
Pharmaceutical Controversies and the Performative Value of Uncertainty
Pharmacovigilance and Post-Black Market Surveillance
Alienating evidence based medicine vs. innovative medical device marketing
Sociology of pharmaceuticals development and regulation
Doriden von Ciba’
A historical argument for regulatory failure in the case of Primodos and other hormone pregnancy tests
Desperately seeking cancer drugs
A pill for every ill
| Unique citing works | 13 |
|---|---|
| Citations per year | 0,68 |
| Citation span | 2007 - 2021 (15) |
| Citation velocity | historical |
| Highly cited | No |
| Citation types | Neutral: 13 |